[go: up one dir, main page]

WO2009073805A3 - Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences - Google Patents

Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences Download PDF

Info

Publication number
WO2009073805A3
WO2009073805A3 PCT/US2008/085568 US2008085568W WO2009073805A3 WO 2009073805 A3 WO2009073805 A3 WO 2009073805A3 US 2008085568 W US2008085568 W US 2008085568W WO 2009073805 A3 WO2009073805 A3 WO 2009073805A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
aglycosylated
nucleotide sequences
encoding nucleotide
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/085568
Other languages
French (fr)
Other versions
WO2009073805A2 (en
Inventor
Joseph D Kittle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verdezyne Inc
Original Assignee
Verdezyne Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verdezyne Inc filed Critical Verdezyne Inc
Publication of WO2009073805A2 publication Critical patent/WO2009073805A2/en
Publication of WO2009073805A3 publication Critical patent/WO2009073805A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are therapeutic polypeptides such as antibodies with reduced glycosylation and methods of designing and synthesizing the same. The therapeutic polypeptides can have reduced effector functions, and also can have additional advantages including, but not limited to, more efficient expression, purification, and improved patient response. In some embodiments, the polypeptide is a recombinantly- produced humanized antibody targeting a cytokine with specificity for a particular cytokine relative to other naturally-occurring human antigens, wherein the antibody has a constant region, and wherein the constant region is aglycosylated.
PCT/US2008/085568 2007-12-04 2008-12-04 Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences Ceased WO2009073805A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99229107P 2007-12-04 2007-12-04
US60/992,291 2007-12-04

Publications (2)

Publication Number Publication Date
WO2009073805A2 WO2009073805A2 (en) 2009-06-11
WO2009073805A3 true WO2009073805A3 (en) 2009-07-30

Family

ID=40627568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/085568 Ceased WO2009073805A2 (en) 2007-12-04 2008-12-04 Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences

Country Status (1)

Country Link
WO (1) WO2009073805A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011201157C1 (en) * 2002-12-24 2017-09-07 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
EP2546267A1 (en) * 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
MX2015003007A (en) 2012-09-07 2015-06-05 Coherus Biosciences Inc Stable aqueous formulations of adalimumab.
CN103446583B (en) * 2013-03-21 2015-11-18 百奥泰生物科技(广州)有限公司 A kind of people's antibody preparation for the treatment of TNF-alpha associated disorders
US10376582B2 (en) * 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
AU2017213775A1 (en) * 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDERSEN D C ET AL: "Production technologies for monoclonal antibodies and their fragments", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 15, no. 5, 1 October 2004 (2004-10-01), pages 456 - 462, XP004588033, ISSN: 0958-1669 *
MAZOR YARIV ET AL: "Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 5, 1 May 2007 (2007-05-01), pages 563 - 565, XP002488027, ISSN: 1087-0156, [retrieved on 20070415] *
SIMMONS L C ET AL: "Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 263, no. 1-2, 1 May 2002 (2002-05-01), pages 133 - 147, XP004354391, ISSN: 0022-1759 *
STEINER DANIEL ET AL: "Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display", NATURE BIOTECHNOLOGY, vol. 24, no. 7, July 2006 (2006-07-01), pages 823 - 831, XP009117243, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
WO2009073805A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2009073805A3 (en) Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010055366A3 (en) Anti-human il-21 monoclonal antibodies
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2007092939A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
EA200971056A1 (en) PRODUCTION OF RECOMBINANT PROTEINS IN EBX® BIRD CELLS
WO2005003175A3 (en) Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ597692A (en) Anti-IGF antibodies
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2003068924A3 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2005012493A3 (en) Anti-cd19 antibodies
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
EP2143795A3 (en) Anti-CD20 monoclonal antibody
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2010124163A3 (en) Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
MY183804A (en) Humanized anti-factor d antibodies
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
NZ603883A (en) Method for preparing antibodies having improved properties
NZ705848A (en) Anti-cd38 antibodies
UA97516C2 (en) Fully human anti-vap-1 monoclonal antibody
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856303

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 08856303

Country of ref document: EP

Kind code of ref document: A2